Compare Incyte Corporation (INCY) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NIO Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while NIO Inc. trades at $3.58 (market cap $8.62B). The key difference: Incyte Corporation is far larger — about 2.7× NIO Inc.'s market cap, and Incyte Corporation is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and NIO Inc. for 81 Days on average.
| INCY | NIO | |
|---|---|---|
Market Cap | $22.85B | $8.62B |
Volume | 1,927,029 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $7.46 |
52-Week Low | $83.80 | $3.37 |
Typical Hold Time | 33 Days | 81 Days |
Enterprise Value | $18.35B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
NIO trades at $3.41, down 3.67% today and near its 52-week low, reflecting bearish technical signals. The company reported Q3 2026 deliveries up 25.4% but continues to post net losses, with a -4.17% net income margin in 2026. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38 billion for NIO Power, aiming to expand charging infrastructure amid a competitive EV price war in China.
The outlook remains challenging due to persistent losses and high debt, though revenue growth and analyst consensus suggest long-term potential. Risks include intense competition, margin pressure, and macroeconomic headwinds. With a $6.23 average price target, analysts see 83% upside, but investors must weigh profitability improvements against ongoing cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
